The risk of rhabdomyolysis in the general population is elevated by the in creased prevalence of statin use. As the presentation of rhabdomyolysis is varied, there is a risk of delayed diagnosis leading to patient complications and increased healthcare costs. Creatine kinase (CK) alone is not sufficiently predictive for risk stratification. Beyond serum CK, other biomarkers such as transaminases may be used as surrogates to evaluate rhabdo myolysis severity and predict complication risks.
Introduction
rhabdomyolysis is precipitated by skeletal muscle breakdown leading to the release of creatine kinase (CK) into the bloodstream. 1 in addition to CK elevation, the breakdown of skeletal muscles also leads to leakage of intracellular contents such as potassium, aldolase, phosphate, myo globin, lactate dehydrogenase (lDH) and aspartate aminotransferase (aSt). 1 The presentation of rhabdomyolysis is varied, with some individuals developing myalgia and muscle weakness while others are asymptomatic. 2 if untreated, patients may progress to acute kidney injury (aKi), com partment syndrome and eventual demise. 1, 2 The risk of rhabdomyolysis in the general popu lation is further elevated as more patients are placed on statins to control cardiovascular dis ease risk factors. 3 Statininduced rhabdomyolysis, resulting in hospital admission, is a concern and adds to healthcare costs. 4 J OUrNal OF PrimarY HealtH Care 317
Given the potential for poor outcomes with delayed treatment in patients with rhabdomyolysis, 1 it is important for clinicians to stratify patients based on their risk of complications. Biomarkers, such as CK, that directly correlate with the degree of muscle injury, have been studied. 1,2 mcmahon et al. showed that patients with high serum CK (>40,000 iU/l) are at high risk for aKi, and early hydration is vital to prevent complications. 5 However, CK levels alone are not sufficiently predictive to stratify risk. 5 Beyond serum CK, other routine biomarkers, such as electrolytes, transaminases and urine myoglobulin may be performed in patients with rhabdomyolysis. Potentially, these markers may be used as surrogates to evaluate the severity of rhabdomyolysis and predict the risk of complications. Our study objective was to find out which routinely performed biomarkers are associated with elevated serum CK, thereby facilitating clinicians in achieving an earlier diagnosis of rhabdomyolysis, stratifying patients with higher risk of complications and instituting early treatment of these patients to prevent disease progression. 1 Therefore, we aimed to find out which routinely performed biomarkers are associated with peak serum CK and severity of rhabdomyolysis. This knowledge will allow increased vigilance in anticipating rhabdomyolysis in statin users.
Methods
Study design a retrospective study was conducted at an acute care hospital in Singapore. Based on the hospital's medical records, hospitalized patients from June 2008 to may 2011 were screened for incidences of statininduced rhabdomyolysis. The international Classification of Diseases, Ninth revision, Clini cal modification (iCD9Cm) code for a primary diagnosis of other disorders of muscle, ligament and fascia (728.89, including rhabdomyolysis) was used to identify potential cases of rhabdo myolysis and myopathy. The study was approved by institutional review Board with a waiver for patient consent.
Study group
The inclusion criteria were: (1) patients diagnosed clinically with statininduced rhabdomyolysis; and (2) peak CK levels of ≥1000 iU/l. 2 Patients with postoperational rhabdomyolysis, acute myocardial infarction and who suffered from road traffic accidents were excluded. Figure 1 shows a flow diagram to illustrate patient selec tion into this study. 6
Data collection
Data were retrieved from the hospital's electronic clinical data monitoring system and patients' casenotes. information extracted included demographics data and laboratory test results including peak CK levels, urine myoglobulin,
WHAT GAP THIS FILLS
What is already known: Statin use is prevalent in an ageing popula tion. Routine liver function tests are necessary to monitor liver function.
What this study adds: Aspartate aminotransferase (AST) is associated in statininduced rhabdomyolysis patients. AST may be useful to look out for rhabdomyolysis. 
Statistical analysis
Univariable linear regression analysis was performed to identify variables associated with an increase in peak CK in our study population. Variables found to have a P value of < 0.1 were subsequently included in a multivariable linear regression model. Variables with P values < 0.05 in the final model were considered statistically significant.
We defined severe rhabdomyolysis as peak CK ≥5000 iU/l, while mild rhabdomyolysis was defined as peak CK of 1000-5000 iU/l. 7 Variables associated with an increase in peak CK From the univariable linear regression model, alanine aminotransferase (alt) (P < 0.001; b = 141.72) and aSt (P < 0.001; b = 76.52) were selected for the multivariable linear regression model (table 2) . Creatinine, urea, potassium, calcium, phosphate and urine myoglobulin were not considered for the multivariable model as their univariable P values were >0.1. Only aSt was found to be positively associated with peak CK levels in the multivariable linear regression model after adjusting for alt levels (P = 0.002; b = 83.18) (table 2). The results were similar when the data were analysed with both forward and backward stepwise regression.
Variables associated with severity of rhabdomyolysis
Similar results were found when we binarised the peak CK values to define severity of rhabdo myolysis. From the univariable logistics regres sion model, alt (P = 0.022; Or = 1.01) and aSt (P = 0.004; Or = 1.01) were selected for the multi variable logistics regression model (table 3) . Cre atinine, urea, potassium, calcium, phosphate and urine myoglobulin were not considered for the multivariable model as their univariable Pvalues were >0.1. Only aSt was found to be positively associated with severity of rhabdomyolysis in the multivariable logistics regression model after adjusting for alt levels (P = 0.015; Or = 1.01) (table 3) . The results were similar when the data were analysed with both forward and backward stepwise regression.
Discussion
This is the first research report examining biomarkers associated with the peak CK values and severity of rhabdomyolysis in patients with statininduced rhabdomyolysis, while adjust ing with a comprehensive set of variables. We found aSt to be associated with peak CK levels. This is congruent with the understanding that rhabdomyolysis leads to the leakage of intra cellular contents from skeletal muscles, which precipitates aSt elevation. 1,2 aSt is an indirect surrogate for the level of muscle injury. 8 alt, in contrast, is mainly released from liver cells, and is therefore less influenced by changes in muscle metabolism. 7 raurich et al. reported that the mortality rate of patients with rhabdomyolysis was higher in patients with elevated aSt. 9 We postulate that aSt levels may aid in the prediction of complica tion rates among rhabdomyolysis patients and could be used as a stratification tool in addition to peak CK.
There are several limitations in our study. Study participants were recruited from tertiary care, so our findings may not be generalisable to patients with myalgia or myositis who were followed up in primary care. in addition, given that this was a retrospective study, the lack of aldolase level measurements among our patient cohort meant we were unable to incorporate it as a study variable. This is a common issue faced by other studies relying on retrospective data.
Conclusion elevated aSt is associated with raised peak CK levels and severity of rhabdomyolysis. Clinicians may consider ordering an aSt test to aid in the clinical diagnosis of rhabdomyolysis and allow for the early initiation of intravenous hydration for hospitalized rhabdomyolysis patients. Severe rhabdomyolysis was defined as a peak creatine kinase (CK) level of more than 5000 IU/L, whereas mild rhabdomyolysis was defined as peak CK level of more than 1000 to 5000 IU/L. CI (confidence interval); ALT (alanine aminotransferase); AST (aspartate aminotransferase).
